Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (4)
- News (111)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (262)
Show Results For
- All HBS Web
(617)
- People (4)
- News (111)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (262)
Michael Beer
MICHAEL BEER
Mike Beer is the Cahners-Rabb Professor of Business Administration, Emeritus at the Harvard Business School and author Fit to Compete: Why Honest Conversations About Your Company’s... View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Pharmaceutical Industry; United States; United Kingdom; Australia; Germany; Europe
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- 2011
- Working Paper
Managing Political Risk in Global Business: Beiersdorf 1914-1990
By: Geoffrey Jones and Christina Lubinski
This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks... View Details
Keywords: History; Risk Management; Business History; Multinational Firms and Management; Corporate Strategy; Intellectual Property; Cooperation; Business and Government Relations; Germany
Jones, Geoffrey, and Christina Lubinski. "Managing Political Risk in Global Business: Beiersdorf 1914-1990." Harvard Business School Working Paper, No. 12-003, July 2011.
- 06 Jun 2023
- Cold Call Podcast
The Opioid Crisis, CEO Pay, and Shareholder Activism
- 02 Aug 2011
- First Look
First Look: August 2
pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
Keywords: Sean Silverthorne
- 03 Apr 2007
- First Look
First Look: April 3, 2007
the inception of the company in 1999. eClinicalWorks was a privately run business in the healthcare information technology field that took in $25 million in revenue in 2005. Revenues for 2006 were projected to reach $40 million. This... View Details
Keywords: Martha Lagace
- Web
Faculty & Advisors | MBA
Alexion Pharmaceuticals from 2017-2019. At Biogen, Paul oversaw rapid growth in the company as it expanded it's products and pipeline. During his tenure as CFO, Biogen grew total return to shareholders at a... View Details
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory... View Details
Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Health Industry; United States
Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
Dafna Bearson
Dafna Bearson is a doctoral candidate in the Strategy Unit at Harvard Business School. Her research interests lie at the intersection of strategy and innovation. Specifically, her research focuses on intellectual property commercialization strategy in startups... View Details
- 04 Jun 2013
- Working Paper Summaries
Prosocial Bonuses Increase Employee Satisfaction and Team Performance
Krishna G. Palepu
KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean at the... View Details
Max H. Bazerman
Max H. Bazerman is Jesse Isidor Straus Professor of Business Administration at the Harvard Business School. His recent books... View Details
- November 2016 (Revised February 2017)
- Case
CVS Health: Redefining the Value Proposition
By: Michael E. Porter, Jorge Ramirez-Vallejo and Alexandra Houghtalin
This case explores how a company can use shared value as a lens to think about competition and strategy choices in a challenging and evolving industry. The case takes a historical look at the structure of the retail pharmacy industry and the changing nature of rivalry... View Details
Keywords: Shared Value; Pharmacy; Health Care; Strategy; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
Porter, Michael E., Jorge Ramirez-Vallejo, and Alexandra Houghtalin. "CVS Health: Redefining the Value Proposition." Harvard Business School Case 717-436, November 2016. (Revised February 2017.)
- 07 Jan 2010
- Working Paper Summaries
International Differences in the Size and Roles of Corporate Headquarters: An Empirical Examination
- June 2024 (Revised December 2024)
- Case
Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital
By: Joshua D. Margolis and Ahmed Dahawy
Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
Margolis, Joshua D., and Ahmed Dahawy. "Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital." Harvard Business School Case 424-075, June 2024. (Revised December 2024.)
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)